|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 9/20 | (2006.01) |
| A61K 9/2054 | (2013.01) | ||
| A61K 31/47 | (2006.01) | ||
| A61K 31/47 | (2013.01) | ||
| A61K 31/194 | (2006.01) | ||
| A61K 31/194 | (2013.01) | ||
| A61P 35/00 | (2006.01) | ||
| A61P 35/00 | (2018.01) |
| (11) | Patento numeris | 2981263 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 14724909.8 |
| Europos patento paraiškos padavimo data | 2014-04-04 | |
| (97) | Europos patento paraiškos paskelbimo data | 2016-02-10 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2022-06-29 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/US2014/033016 |
| Data | 2014-04-04 |
| (87) | Numeris | WO 2014/165786 |
| Data | 2014-10-09 |
| (30) | Numeris | Data | Šalis |
| 201361808511 P | 2013-04-04 | US |
| (72) |
WEITZMAN, Aaron , US
|
| (73) |
Exelixis, Inc. ,
1851 Harbor Bay Parkway, Alameda, CA 94502,
US
|
| (54) | CABOZANTINIB DOSAGE FORM AND USE IN THE TREATMENT OF CANCER |
| CABOZANTINIB DOSAGE FORM AND USE IN THE TREATMENT OF CANCER |